

Confirmation of Change in ADS Ratio

AstraZeneca PLC (the "**Company**") today confirmed that the intended ratio change to its NYSE-listed sponsored Level 2 American Depositary Receipt ("**ADR**") programme announced on 26 June 2015 has now become effective. With effect from 27 July 2015, the Company's American Depositary Share ("**ADS**") ratio is two (2) ADSs per one (1) Ordinary Share. The former ratio was one (1) ADS per one (1) Ordinary Share. There are no changes to the underlying Ordinary Shares.

ADS holders at the close of business New York time on the record date, 22 July 2015, received a distribution of one additional ADS for every ADS held. No action was required by ADS holders to effect this change.

Contact details for Citibank, N.A., the Company's ADR depository, can be found below.

AC N Kemp
Company Secretary

27 July 2015

CONTACT

Citibank Shareholder Services

PO Box 43077	Tel (toll free in the US): +1-888-697-8018
Providence	Tel (outside the US): +1-781-575-4555
RI 02940-3077	
US	

Media Enquiries

Esra Erkal-Paler	+44 20 7604 8030 (UK/Global)
Jacob Lund	+46 8 553 260 20 (Sweden)
Michele Meixell	+ 1 302 885 6351 (US)

Investor Enquiries

UK

Thomas Kudsk Larsen		+44 20 7604 8199	mob: +44 7818 524185
Eugenia Litz	Respiratory, Inflammation and Autoimmunity	+44 20 7604 8233	mob: +44 7884 735627
Nick Stone	Cardiovascular and Metabolic Disease	+44 1763 263 994	mob: +44 7717 618834
Karl Hård	Oncology	+44 20 7604 8123	mob: +44 7789 654364
Craig Marks	Infection, Neuroscience and Gastrointestinal Disease	+44 20 7604 8591	mob: +44 7881 615764
Christer Gruvris		+44 20 7604 8126	mob: +44 7827 836825

US

Dial / Toll-Free	301-398-3251	866-381-7277
------------------	--------------	--------------